Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Vincent Rajkumar

Showing results (371-380 of 566) with videos related to

Pageof 57
Sort By:
Blood|September 23, 2008
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotypingDavid C Johnson, Sophie Corthals, Christine Ramos, et al.
British Journal of Haematology|November 24, 2011
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myelomaMeaghan L Khan, Craig B Reeder, Shaji K Kumar, et al.
Mayo Clinic Proceedings|May 10, 2017
Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic ExperienceTaxiarchis V Kourelis, Robert A Kyle, David Dingli, et al.
American Journal of Hematology|June 25, 2016
Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluationYi L Hwa, Shaji K Kumar, Morie A Gertz, et al.
American Journal of Hematology|March 15, 2016
Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experienceTaxiarchis V Kourelis, Francis K Buadi, Shaji K Kumar, et al.
JCO Oncology Practice|May 17, 2022
Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard CareSurbhi Sidana, Cristine Allmer, Melissa C Larson, et al.
Ejhaem|November 29, 2023
Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trialPaul G Richardson, Thierry Facon, Christopher P Venner, et al.
British Journal of Haematology|February 16, 2019
Substratification of patients with newly diagnosed standard-risk multiple myelomaMoritz Binder, S Vincent Rajkumar, Rhett P Ketterling, et al.
Blood Advances|April 12, 2022
Outcomes after biochemical or clinical progression in patients with multiple myelomaSarah Goldman-Mazur, Alissa Visram, Prashant Kapoor, et al.
Lancet (London, England)|November 19, 2019
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 studyMichel Attal, Paul G Richardson, S Vincent Rajkumar, et al.
Pageof 57

Showing results (371-380 of 566) with videos related to

Sort By:
Pageof 57
Blood|September 23, 2008
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotypingDavid C Johnson, Sophie Corthals, Christine Ramos, et al.
British Journal of Haematology|November 24, 2011
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myelomaMeaghan L Khan, Craig B Reeder, Shaji K Kumar, et al.
Mayo Clinic Proceedings|May 10, 2017
Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic ExperienceTaxiarchis V Kourelis, Robert A Kyle, David Dingli, et al.
American Journal of Hematology|June 25, 2016
Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluationYi L Hwa, Shaji K Kumar, Morie A Gertz, et al.
American Journal of Hematology|March 15, 2016
Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experienceTaxiarchis V Kourelis, Francis K Buadi, Shaji K Kumar, et al.
JCO Oncology Practice|May 17, 2022
Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard CareSurbhi Sidana, Cristine Allmer, Melissa C Larson, et al.
Ejhaem|November 29, 2023
Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trialPaul G Richardson, Thierry Facon, Christopher P Venner, et al.
British Journal of Haematology|February 16, 2019
Substratification of patients with newly diagnosed standard-risk multiple myelomaMoritz Binder, S Vincent Rajkumar, Rhett P Ketterling, et al.
Blood Advances|April 12, 2022
Outcomes after biochemical or clinical progression in patients with multiple myelomaSarah Goldman-Mazur, Alissa Visram, Prashant Kapoor, et al.
Lancet (London, England)|November 19, 2019
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 studyMichel Attal, Paul G Richardson, S Vincent Rajkumar, et al.
Pageof 57